Atlantic Lipid Lowering Treatment Optimization Program
Recruiting · NCT06439654 · Interventional (participants receive a specific treatment) · Lead sponsor: Atlantic Health System
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup is to enhance the treatment of lipid disorders in those patients with abnormal lipid levels by improving access to resources at the primary care practice level and specialty level. We aim to develop a model for primary and secondary prevention that integrates guidelines for treatment at the practice level. Our primary objective is to identify high-risk patients by utilizing the electronic health record and partnering with patients' primary care providers to provide comprehensive medical management.
Who can take part
Inclusion criteria
- LDL-C ≥160 mg/dL
- Untreated LDL-C ≥190 with family history of CAD
- Prior MI and currently without optimized lipid-lowering therapy
- Family history of CAD in first degree relative
- Personal history of CAD
- Untreated triglycerides \>500
- Elevated Lp(a) and/or high calcium scores
- Consenting individuals
Exclusion criteria
- Individuals who are pregnant
- Individuals who are incarcerated
- Individuals with a terminal illness
- Individuals who do not consent
Where it is running
2 locations listed across 1 US state.
- Atlantic Medical Group - Clark, New Jersey, United States
- Atlantic Medical Group - Springfield, New Jersey, United States